TLDR
- Clearmind Medicine’s CMND-100 met its primary endpoint in a Phase I/IIa clinical trial for Alcohol Use Disorder
- The third cohort showed a strong safety profile with no serious adverse events, even at the highest doses tested
- CMND stock jumped over 100%, trading around $1.44 after the announcement
- The trial is an FDA-approved, multinational study evaluating safety, tolerability, and early efficacy in moderate to severe AUD patients
- The Data and Safety Monitoring Board approved continuation of the trial after reviewing safety data
Clearmind Medicine (CMND) saw its stock more than double on Monday after the company announced that its lead drug candidate, CMND-100, met the primary endpoint in an FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder.
The stock was trading around $1.44 at time of publication, up roughly 100% on the day.
The trial’s third cohort showed a strong safety and tolerability profile, even at the highest doses tested so far. No serious adverse events were reported.
The company said the results were consistent with earlier cohorts, suggesting the drug’s safety profile holds up as doses increase.
CMND-100 is a non-hallucinogenic, MEAI-based oral drug candidate. It is being developed as a treatment for moderate to severe Alcohol Use Disorder.
The Phase I/IIa study is a multinational, multicenter trial. It is designed to evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy.
Trial Clears Key Hurdle
Meeting the primary endpoint in the dose-escalation stage is a key step forward. Clearmind said this outcome supports continued advancement of CMND-100 as a treatment option.
The company’s Data and Safety Monitoring Board reviewed the safety data and approved the trial to continue. A total of 18 participants have now completed treatment and follow-up.
Clearmind’s approach focuses on neuroplastogen-derived therapeutics that do not carry the hallucinogenic effects associated with other psychedelic-based treatments.
Where the Company Stands
Before Monday’s move, the stock had fallen nearly 50% over the prior week. It was trading at just $0.72 with a market cap of roughly $1.5 million.
The company holds more cash than debt and has liquid assets that exceed its short-term obligations. That gives it some financial runway as clinical work continues.
Clearmind’s intellectual property portfolio includes 19 patent families and 31 granted patents. The company also recently filed a patent application with the Indian Patent Office for psychedelic-based compounds covering mental health and addiction treatment.
That filing is tied to a licensing agreement with Yissum Research Development Company, the commercialization arm of the Hebrew University of Jerusalem.
CMND was trading at $1.44, up 100.06%, at time of publication, according to Benzinga Pro data.
šØ Our April Stock Picks Are Live!
A new month means new opportunities. Our analysts have just released their top stock picks for April, highlighting companies with strong momentum that rank highly on our KO Score algorithm. Weāre also now sharing trade ideas for both long-term and short-term investors, giving you more ways to spot potential opportunities in the market.
Sign up to Knockout Stocks today and get 50% off to unlock the full list and see which stocks made the cut.
Use coupon code Special50 for your exclusive discount!
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
